自体 TIL（肿瘤浸润淋巴细胞）在复发/难治性卵巢癌、结直肠癌和胰腺导管腺癌中的疗效与安全性

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal a

在 4-1BB 和 CD3 激动作用的辅助下制备的 TIL 是可行的，且治疗未伴随新的安全性信号。

Neoleukin-2/15 装甲 CAR-NK 细胞通过 c-Myc/NRF1 激活在实体瘤中维持优越的治疗效果

Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation.

体外及卵巢癌小鼠异种移植模型中对胶质母细胞瘤、乳腺癌和胰腺癌有效的嵌合抗原受体 (CAR)-NK92 细胞

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of o

我们的结果表明，CD44v6-CAR-NK92 细胞可能是一种有吸引力的治疗实体瘤的治疗剂。

rhIL-7-hyFc（一种长效白细胞介素-7）提升 CAR-T 细胞治疗实体瘤的疗效

rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.

本研究为 NT-I7 联合 CAR-T 细胞治疗人类实体瘤提供了依据。

TROP2-CAR-NK（CAR-NK 细胞）治疗胰腺癌、卵巢癌：I/II 期临床试验

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian

这是一项 I/II 期注册临床试验，评估 CAR-NK 细胞治疗胰腺癌、卵巢癌的安全性、可行性及初步疗效。当前状态：进行中（不再招募）。计划入组 51 例。试验地点：美国 · 休斯顿（共 1 个中心）。登记号：NCT05922930。

双特异性 c-Met/PD-1 CAR-T 细胞对实体瘤具有增强的治疗效果

Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.

具有增强肿瘤浸润与持久性的高效抗间皮素 hYP218 CAR-T 细胞的开发及其实体瘤治疗

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treatin

三级淋巴结构通过重塑冷肿瘤微环境实现从冷到热的转变

Tertiary lymphoid structures achieve 'cold' to 'hot' transition by remodeling the cold tumor microenvironment.